MCPIP1 reduces HBV-RNA by targeting its epsilon structure

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis B virus (HBV) causes chronic liver disease, cirrhosis, and liver cancer.
• The proinflammatory cytokine IL-1β reduces HBV RNA, but the mechanism is unclear.
• Understanding HBV replication control is vital for developing antiviral therapies.

Purpose of the Study:

• To investigate the role of Monocyte chemotactic protein-1-induced protein 1 (MCPIP1) in regulating HBV RNA levels.
• To elucidate the mechanism by which MCPIP1 affects HBV RNA.
• To determine if MCPIP1 mediates the antiviral effect of IL-1β against HBV.

Main Methods:

• Quantified MCPIP1 expression in HBV-infected patient and mouse liver tissues.
• Assessed HBV RNA levels following MCPIP1 overexpression or ablation in hepatocytes.
• Investigated the functional domains of MCPIP1 and the HBV RNA epsilon structure using cell-free assays.
• Examined the impact of MCPIP1 knockout on IL-1β's anti-HBV activity.

Main Results:

• MCPIP1 expression was elevated in HBV-infected liver tissues.
• MCPIP1 overexpression decreased HBV RNA, while MCPIP1 ablation increased HBV production.
• MCPIP1's RNase activity and oligomerization domains were essential for reducing HBV RNA.
• MCPIP1 directly cleaved the HBV RNA epsilon structure in vitro.
• MCPIP1 knockout diminished the anti-HBV effect of IL-1β.

Conclusions:

• MCPIP1 directly reduces HBV RNA levels in hepatocytes.
• MCPIP1 functions as an RNase that targets the HBV RNA epsilon structure.
• MCPIP1 is a key mediator of the anti-HBV activity of IL-1β, acting downstream of this cytokine.